Clinical trials: Hepatic Cirrhosis
Colorectal Cancer, Coffee
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery…
- Conditions
- Colorectal Cancer, Coffee, Gastrointestinal Microbiome, Stenosis
- Trial name
- COMMENCER (NCT05692024)
- Testing
- Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Decompensated Liver Cirrhosis
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores.
- Trial name
- NCT07002827
- Testing
- Darbepoetin, G-CSF, Lactulose
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Pruritus
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
- Trial name
- NCT04950127
- Testing
- Linerixibat
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 238 people
- Sponsor
- GlaxoSmithKline
Minimal Hepatic Encephalopathy
Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy
This research proposes to find whether the probiotic lactobacillus GG is safe and well tolerated in patients with minimal hepatic encephalopathy. We also want to get insight into the mechanisms of action of LGG.
- Trial name
- NCT00992290
- Testing
- Lactobacillus GG
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Virginia Commonwealth University
Chronic Hepatitis B
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown.
- Trial name
- NCT04939441
- Testing
- Tenofovir alafenamide
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Jidong Jia
Fibrosis, Cirrhosis
Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography Of Fibrosis And Cirrhosis
Fatty liver is a condition in which fat builds up in liver. it is very common health issue.it is major public health problems in the world. there is particular concern because fatty liver causes mortality among patients.
- Trial name
- NCT06749522
- Testing
- high resolution ultrasonography
- Where
- Pakistan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Superior University
Hepatocellular Carcinoma
Evaluation of Diagnostic Accuracy of CEUS for HCC Diagnosis
This study aims to compare the diagnostic accuracy of Contrast-enhanced ultrasound (CEUS) for diagnosing hepatocellular carcinoma (HCC) with that of gadoxetic acid-enhanced liver magnetic resonance imaging (MRI) using…
- Trial name
- NCT03742453
- Testing
- contrast-enhanced ultrasound, EOB-MRI
- Where
- South Korea
- Volunteers
- 117 people
- Sponsor
- Seoul National University Hospital
Portal Vein Thrombosis, Liver Cirrhosis
The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT
The purpose of this study is to determine the effect and safety of anticoagulation after endoscopic therapy in cirrhotic patients with portal vein thrombosis and to explore its effect on long-term rebleeding rate and mortality.
- Trial name
- NCT02630095
- Testing
- Nadroparin Calcium and Warfarin, Doppler ultrasound and CT
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Zhongshan Hospital
Ascites, Liver Cirrhosis
Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites
The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites and the correction of hyponatraemia when used concomitantly with a standard dose regimen of spironolactone.
- Trial name
- Hypo~CAT (NCT00501722)
- Testing
- satavaptan (SR121463B)
- Where
- 13 sites in United States, Argentina and 11 more
- Volunteers
- 110 people
- Sponsor
- Sanofi
Liver Cirrhosis, Hepatitis C, Chronic
Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C
Study to assess the antiviral efficacy, pharmacokinetics, and tolerability of 200 mg BILN 2061 ZW in a polyethylene glycol 400 (PEG 400: ethanol) drinking solution given orally for two days bid to patients with cirrhosis and…
- Trial name
- NCT02226939
- Testing
- BILN 2061 ZW
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Hepatocellular
Risk of Hepatocellular Carcinoma in Patient With Liver Cirrhosis
Purpose of the study is to determine transcriptomics, metabolomics and proteomics features of liver cirrhotic tissue in patients with hepatocellular carcinoma (HCC) and to find a correlation with the risk of developing HCC and…
- Trial name
- NCT03083002
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- University of Modena and Reggio Emilia
Primary Biliary Cirrhosis
Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid
Ursodeoxycholic acid (UDCA) has been the only treatment for PBC approved by US and European drug administrations. Long-term use of UDCA(13-15 mg/kg/day) in patients with PBC improves serum liver biochemistries and survival free…
- Trial name
- NCT02823366
- Testing
- Fenofibrate, UDCA
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Primary Biliary Cirrhosis
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
Up to 40% of patients with PBC have an inadequate response to standard treatment with UDCA, hence bezafibrate, a PPAR-agonist is being introduced as add-on therapy in these patients.
- Trial name
- NCT04514965
- Testing
- Blood sampling, Fibroscan, Question
- Where
- 2 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Glucose Metabolism Disorders, Liver Fibrosis
Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents
Chronic hepatitis C infection is associated with changes of glucose metabolism end increased frequency of impaired glucose tolerance. This might be a additional risk factor for disease and fibrosis progression.
- Conditions
- Glucose Metabolism Disorders, Liver Fibrosis, Hepatitis C
- Trial name
- NCT03908294
- Testing
- Lab tests, non-invasive fibrosis (Fibroscan/ARFI)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Porto-Sinusoidal Vascular Disease, Cirrhosis Due to Hepatitis B
TIPS for Platinum-Related Porto-Sinusoidal Vascular Disease With Variceal Bleeding
Platinum-based compounds are associated with several adverse effects, including Porto-Sinusoidal Vascular Disease (PSVD). Therapeutic strategies for platinum-related PSVD are based on the management of complications seen in…
- Conditions
- Porto-Sinusoidal Vascular Disease, Cirrhosis Due to Hepatitis B, Esophageal Variceal Rebleeding, Gastric Variceal Bleeding
- Trial name
- NCT06635122
- Testing
- Transjugular intrahepatic portosystemic shunt, Endoscopic treatment
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Air Force Military Medical University, China
Hepatocellular Carcinoma, Hepatocellular Cancer
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis
- Trial name
- NCT05064553
- Testing
- Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
- Where
- 76 sites in United States
- Volunteers
- 2,990 people
- Sponsor
- Exact Sciences Corporation
Portal Hypertension Related to Cirrhosis
EUS-guided Response Assessment to NSBB
The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically…
- Trial name
- NCT06513195
- Testing
- endoscopic ultrasound-guided portal pressure measurement
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Liver Cirrhosis
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction
Acute upper gastrointestinal bleeding (AUGIB) is a common complication in the decompensated stage of liver cirrhosis, of which approximately 70% is acute variceal bleeding (AVB) caused by portal hypertension.
- Trial name
- NCT07252401
- Testing
- 2-4 mg of terlipressin, 3 mg of somatostatin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- General Hospital of Shenyang Military Region
Pulmonary Hypertension
Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a condition characterized by an increased pulmonary vascular resistance that can lead to right heart failure and death.
- Trial name
- NCT01729611
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- The Cleveland Clinic
NASH - Nonalcoholic Steatohepatitis
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
This is an open-label, single-dose study to evaluate the PK profile of the liquid SC formulation of BIO89-100 in approximately 8 male and female subjects with NASH with compensated cirrhosis.
- Trial name
- NCT05022693
- Testing
- BIO89-100
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- 89bio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.